69304-42-3

Usage

Uses

Used in Biochemistry and Molecular Biology Research:
(+)-3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)cytidine is used as a research tool for studying the structure and function of nucleic acids, specifically RNA and DNA. It is utilized to investigate the interactions and dynamics of these molecules, as well as to understand the impact of chemical modifications on their behavior.
Used in Nucleic Acid Manipulation:
In the field of nucleic acid research, (+)-3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)cytidine serves as a key component for manipulating nucleic acids in a controlled and precise manner. Its unique silicon-based linker molecule enables researchers to explore the properties and mechanisms of nucleic acids, contributing to advancements in molecular biology and related disciplines.
Used in Pharmaceutical Development:
Although not explicitly mentioned in the provided materials, the study and manipulation of nucleic acids are often crucial in the development of new pharmaceuticals, particularly in the areas of gene therapy and antisense therapies. (+)-3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)cytidine, by aiding in the understanding of nucleic acid behavior, could indirectly contribute to the development of novel therapeutic agents targeting genetic disorders or diseases influenced by nucleic acid function.

Upstream product

• 119694-66-5 4-O-<(2,4,6-triisopropylphenyl)sulfonyl>-3',5'-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)uridine 
• 69304-37-6 1,3-Dichloro-1,1,3,3-tetraisopropyldisiloxane 
• 65-46-3 CYTIDINE 
• 58-96-8 uridine 
• 69304-43-4 1-[3,5-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-β-D-ribofuranosyl]-N⁴-benzoylcytosine 
• 74-89-5 methylamine 
• 85335-73-5 N₄-acetyl-3',5'-O-(tetraisopropyldisiloxane-1,3-diyl)cytidine 
• 75-04-7 ethylamine 
• 107-10-8 propylamine 

Downstream Products

• 1054642-81-7 N-[2-Oxo-1-((2R,3R,3aR,9aR)-5,5,7,7-tetraisopropyl-3-trimethylsilanyloxy-tetrahydro-1,4,6,8-tetraoxa-5,7-disila-cyclopentacycloocten-2-yl)-1,2-dihydro-pyrimidin-4-yl]-benzamide 
• 147490-72-0 4-N-benzoyl-2'-O-<1-(2-fluorophenyl)-4-methoxypiperidin-4-yl>cytidine 
• 160905-66-8 4-N-benzoyl-2'-O-<1-(2-fluorophenyl)-4-methoxypiperidin-4-yl>-3',5'-O-(tetraisopropyldisiloxane-1,3-diyl)cytidine 
• 160905-74-8 4-N-benzoyl-5'-O-(tert-butyldiphenylsilyl)-2'-O-<1-(2-fluorophenyl)-4-methoxypiperidin-4-yl>cytidine 
• 160905-78-2 4-N-benzoyl-2'-O-<1-(2-fluorophenyl)-4-methoxypiperidin-4-yl>-3'-O-(9-phenylxanthen-9-yl)cytidine 
• 160905-68-0 4-N-benzoyl-5'-O-(tert-butyldiphenylsilyl)-2'-O-<1-(2-fluorophenyl)-4-methoxypiperidin-4-yl>-3'-O-(9-phenylxanthen-9-yl)cytidine 
• 69304-43-4 1-[3,5-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-β-D-ribofuranosyl]-N⁴-benzoylcytosine 
• 87138-60-1 4-N-benzoyl-2'-O-tetrahydropyranyl-3,5'-O-(tetraisopropyldisiloxane-1,3-diyl)cytidine 
• 69359-38-2 5'-O-(dimethoxytrityl)-2'-O-(tetrahydropyranyl)-N⁴-benzoylcytidine 
• 97626-12-5 Phosphoric acid (2R,3R,4R,5R)-5-(4-benzoylamino-2-oxo-2H-pyrimidin-1-yl)-2-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-4-(tetrahydro-pyran-2-yloxy)-tetrahydro-furan-3-yl ester 4-chloro-phenyl ester 
• 97626-09-0 4-N-benzoyl-2'-O-tetrahydropyranyl-5'-O-dimethoxytritylcytidine-3'-(p-chlorophenyl-2-cyanoethyl)phosphate 
• 31505-92-7 N⁴-benzoyl-2'-O-tetrahydropyranylcytidine 
• 90742-22-6 2'-O-(tetrahydropyran-2-yl)-N⁴-anysoylcytidine 
• 90742-21-5 4-Methoxy-N-{2-oxo-1-[(2R,3R,3aR,9aR)-5,5,7,7-tetraisopropyl-3-(tetrahydro-pyran-2-yloxy)-tetrahydro-1,4,6,8-tetraoxa-5,7-disila-cyclopentacycloocten-2-yl]-1,2-dihydro-pyrimidin-4-yl}-benzamide 

Relevant academic research and scientific papers

2′-: O -Trifluoromethylated RNA-a powerful modification for RNA chemistry and NMR spectroscopy

New RNA modifications are needed to advance our toolbox for targeted manipulation of RNA. In particular, the development of high-performance reporter groups facilitating spectroscopic analysis of RNA structure and dynamics, and of RNA-ligand interactions

A novel radiochemical approach to 1-(2'- deoxy-2'-[18F]fluoro-β-D-arabinofuranosyl) cytosine (18F-FAC)

18F-FAC (1-(2'-deoxy-2'-[18F]fluoro-β-D-arabinofuranosyl)-cytosine) is an important 2'-fluoro-nucleoside-based positron emission tomography (PET) tracer that has been used for in vivo prediction of response to the widely used cancer chemotherapy drug gemcitabine. Previously reported synthetic routes to 18F-FAC have relied on early introduction of the 18F radiolabel prior to attachment to protected cytosine base. Considering the 18F radiochemical half-life (110 min) and the technical challenges of multi-step syntheses on PET radiochemistry modular systems, late-stage radiofluorination is preferred for reproducible and reliable radiosynthesis with in vivo applications. Herein, we report the first late-stage radiosynthesis of 18F-FAC. Cytidine derivatives with leaving groups at the 2'-position are particularly prone to undergo anhydro side-product formation upon heating because of their electron density at the 2-carbonyl pyrimidone oxygen. Our rationally developed fluorination precursor showed an improved reactivity-to-stability ratio at elevated temperatures. 18F-FAC was obtained in radiochemical yields of 4.3-5.5% (n = 8, decay-corrected from end of bombardment), with purities ≥98% and specific activities ≥63 GBq/μmol. The synthesis time was 168 min.

MONONUCLEOTIDES HAVING A BIOREVERSIBLE DISULFIDE GROUP

The invention features a mononucleotide comprising a nucleobase bonded to a sugar having a 3'-carbon and a 5'-carbon, where the 5'-carbon is bonded to a phosphorus (V) atom of a phosphate group through an oxygen atom, the phosphorus (V) atom being bonded to (i) a disulfide bioreversible group through an oxygen atom; and (ii) (a) optionally substituted amino, optionally substituted alkoxy, optionally substituted aryloxy, or optionally substituted heteroaryloxy; or (b) the 3'-carbon through an oxygen atom. The invention also features methods of delivering the mononucleotide to a cell and methods of treating a subject having Hepatitis C.

2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to 2'-Methyl Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R, R1, R2 and R3, are as defined herein. The present invention also relat

2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF USEFUL FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to 2′-Cyano Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, R1, R2 and R3 are as defined herein. The present invention also relates to compositions comprising at least one 2′-Cyano Substituted Nucleoside Derivative, and methods of using the 2′-Cyano Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.

2'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to 2′-Azido Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, R1, R2 and R3 are as defined herein. The present invention also relates to compositions comprising at least one 2′-Azido Substituted Nucleoside Derivative, and methods of using the 2′-Azido Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.

2'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to 2'-Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, X, R1, R2 and R3 are as defined herein. The present invention also relates

A new protocol for selective cleavage of acyl protecting groups in 2′-O-modified 3′,5′-O -(Tetraisopropyldisiloxane-1,3-diyl) ribonucleosides

The stability of tetraisopropyldisiloxane-1,3-diyl (TIPDS) protection in nucleosides in ammonia/amine solutions in methanol and ethanol was studied. In ammonia-methanol at ambient temperature significant partial cleavage of TIPDS was observed. When ethano

PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHEIS OF 2'-CYANO-2'-DEOXY-N4-PALMITOYL-1-BETA-D-ARABINOFURANOSYLCYTOSINE

The present invention relates to a process for preparing a compound of formula 682-4, said process comprising the steps of: (i) converting a compound of formula 682-1 into a compound of formula 682-2'; (ii) converting said compound of formula 682-2' into a compound of formula 682-3; and (iii) converting said compound of formula 682-3 into a compound of formula 682-4. Further aspects of the invention relate to the use of the above process in the preparation of 2'-cyano-2'-deoxy-N4 -palmitoyl-1-β-D-arabmofuranosylcytosine, a pyrimidine nucleoside which is therapeutically useful in the treatment and/or prevention of cancer.

INTERMEDIATE AND PROCESSES INVOLVED IN THE PREPARATION OF 2 ' -CYANO-2 ' -DE0XY-N4-PALMIT0YL-1-BETA-ARABIN0FURAN0SYLCYTOSINE

The present invention relates to a process for preparing a compound of formula (682-6'), said process comprising the steps of: formula (682-4), (682-5), (682-6'): (i) converting a compound of formula (682-4) into a compound of formula (682-5); and (ii) converting said compound of formula (682-5) into a compound of formula (682- 6'). Further aspects of the invention relate to the use of the above process in the preparation of 2'-cyano-2'-deoxy-N4-palmitoyl-l-β-D-arabinofuranosylcytosine, a pyrimidine nucleoside which is therapeutically useful in the treatment and/or prevention of cancer.